Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Net Income (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Net Income for 4 consecutive years, with -$25.4 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 39.38% to -$25.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$101.3 million through Dec 2025, down 19.75% year-over-year, with the annual reading at -$101.3 million for FY2025, 19.75% down from the prior year.
  • Net Income hit -$25.4 million in Q4 2025 for Taysha Gene Therapies, up from -$30.9 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$15.0 million in Q4 2023 to a low of -$55.1 million in Q4 2022.
  • Historically, Net Income has averaged -$26.6 million across 4 years, with a median of -$24.2 million in 2023.
  • Biggest five-year swings in Net Income: surged 72.69% in 2023 and later crashed 43.36% in 2024.
  • Year by year, Net Income stood at -$55.1 million in 2022, then surged by 72.69% to -$15.0 million in 2023, then fell by 21.39% to -$18.3 million in 2024, then crashed by 39.38% to -$25.4 million in 2025.
  • Business Quant data shows Net Income for TSHA at -$25.4 million in Q4 2025, -$30.9 million in Q3 2025, and -$24.9 million in Q2 2025.